New Merck pneumococcal vaccine wins FDA approval
The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older.
The vaccine, which will be sold under the name Capvaxive, is designed to protect against pneumococcal pneumonia, which hospitalizes about 150,000 adults in the United States every year and kills about one in 20 who develop it, according to the National Foundation for Infectious Diseases.
Read Original Article: New Merck pneumococcal vaccine wins FDA approval »
